L 410198
Latest Information Update: 05 Oct 2006
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2004 Discontinued - Clinical-Phase-Unknown for Hyperlipidaemia in USA (unspecified route)
- 31 Dec 2004 Discontinued - Clinical-Phase-Unknown for Type-2 diabetes mellitus in USA (unspecified route)
- 26 Feb 2002 Clinical trials in Hyperlipidaemia in USA